Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion – CNS tumours

4589 - Extending temozolomide longer than six cycles in glioblastoma: results of the randomized GEINO-014 TRIAL.


28 Sep 2019


Poster Discussion – CNS tumours


Maria Angeles Salgado


Annals of Oncology (2019) 30 (suppl_5): v143-v158. 10.1093/annonc/mdz243


M.A.V. Salgado1, J.M. Sepulveda Sanchez2, S. del barco3, E. Pineda4, J. Fuster5, M. Navarro Martin6, A. Herrero Ibañez7, M. Alonso8, J. Perez9, C. Mesia10, J. Munoz-Langa11, R. de las Penas Bataller12, S. Peralta13, C. Olier14, P. Pérez-Segura15, A. Estival16, C. Carrato17, C. Saez18, M.J. Gil19, C. Balana20

Author affiliations

  • 1 Medical Oncology, Ramon y Cajal University Hospital, 28029 - Madrid/ES
  • 2 Medical Oncology, University Hospital 12 De Octubre, 28041 - Madrid/ES
  • 3 Medical Oncology, ICO Girona, 17007 - Girona/ES
  • 4 Medical Oncology, Hospital Clinic y Provincial de Barcelona, 08036 - Barcelona/ES
  • 5 Medical Oncology, Hospital Son Espases, Palma de Mallorca/ES
  • 6 Medical Oncology, IBSAL - Instituto de Investigación Biomédica de Salamanca, 37007 - Salamanca/ES
  • 7 Medical Oncology, Hospital Miguel Servet, 50009 - Zaragoza/ES
  • 8 Oncology, Hospital Universitario Virgen del Rocío, Sevilla/ES
  • 9 Biostatistic, ICO hospitalet, Barcelona/ES
  • 10 Medical Oncology, ICO Hospitalet, Barcelona/ES
  • 11 Medical Oncology, Hospital Universitari i Politècnic La Fe, 46026 - Valencia/ES
  • 12 Medical Oncology, Hospital Provincial Castellon, 12002 - Castellón/ES
  • 13 Medical Oncology, Hospital Sant Joan de Reus, Tarragona/ES
  • 14 Medical Oncology, Hospital de Alcorcon, Madrid/ES
  • 15 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 16 Medical Oncology, H German Trias i Pjol, Barcelona/ES
  • 17 Pathology, Hospital Universitari Germans Trias i Pujol, 08916 - Badalona/ES
  • 18 Pathology, German Trias i Pujol, Barcelona/ES
  • 19 Medical Oncology, Institut Català d'Oncologia Hospital Duran i Reynals, 08907 - Barcelona/ES
  • 20 Medical Oncology, Germans Trias i Pujol, Barcelona/ES


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4589


Standard treatment of glioblastoma (GBM) is focal radiation with concomitant and adjuvant temozolomide (TMZ) for 6 cycles. The GEINO-14-01 trial (NCT02209948) investigated the role of extending adjuvant TMZ to 12 cycles in a randomized multicenter study.


Between Aug/2014 and Nov/2018, 166 patients (p) were screened and 159 randomized to extend (80p) or not (79p) TMZ treatment to 12 cycles after proving lack of progression of the disease in the MRI performed before inclusion. The trial was stratified by MGMT status and presence or absence of residual disease (defined as a residual enhancement larger than 1cm on the MRI). The primary endpoint was differences in 6monthsPFS, secondary endpoints were differences in PFS, OS, toxicity, between arms and per stratification factors.


Median age was 60.4 (range 29-83), all p had ECOG≤1 and 86.2% were without DXM treatment. MGMT status: Met: 97 (61%) UnMet:62 (39%). RD yes: 83 (52.2%) and no: 76 (47.8%). At the time of the abstract report 3 patients are still on treatment or control without a documented progression and 5 patients have not been yet 6m in the study: 31 patients (19.5) are still free of progression and 60 patients (37.7%) are still alive. Median (m) PFS has been reached: 7.9 months (95%CI: 6.1-9.8) as well as mOS: 20.9 (95%CI: 17.6-24.1). A methylated status was a factor of better PFS (HR = 0.29, 95% CI 0.46-0.95; p = 0.029) and better OS (HR = 0.43: 95% CI 0.28-0.66; p = 0.000) as well as the absence of residual disease (PFS: HR = 0.84: 95% CI = 0.71-1.01; p = 0.068; OS: HR = 0.77, 95%CI 0.63-0.96; p = 0.019). We didn’t find any difference in PFS (HR = 1.02, 95%CI 0.85-1.21; p = 0.82), or OS (HR = 0.90; 0.73-1.11; p = 0.34) on extending treatment with temozolomide longer than 6 cycles. Toxicity data and final results are expected for the congress.


There is no benefit of continuing TMZ treatment for more than 6 cycles in the adjuvant treatment of glioblastoma. Met status and absence of RD are factors of better SLP after adjuvant treatment. Supported by a Grant of the ISCIII: PI13/01751.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study

GEINO (Grupo Español de Investigación en Neurooncologia).


Supported by a Grant of the ISCIII.


M.A.V. Salgado: Advisory / Consultancy: Lilly; Research grant / Funding (institution): Pfizer; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: pharmamar; Advisory / Consultancy: eisai; Advisory / Consultancy: Celgene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.